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Sister chromatid segregation is triggered at the metaphase-to-anaphase transition by the activation of the
protease separase. For most of the cell cycle, separase activity is kept in check by its association with the
inhibitory chaperone securin. Activation of separase occurs at anaphase onset, when securin is targeted for
destruction by the anaphase-promoting complex or cyclosome E3 ubiquitin protein ligase. This results in the
release of the cohesins from chromosomes, which in turn allows the segregation of sister chromatids to
opposite spindle poles. Here we show that human securin (hSecurin) forms a complex with enzymatically active
protein phosphatase 2A (PP2A) and that it is a substrate of the phosphatase, both in vitro and in vivo.
Treatment of cells with okadaic acid, a potent inhibitor of PP2A, results in various hyperphosphorylated forms
of hSecurin which are extremely unstable, due to the action of the Skp1/Cul1/F-box protein complex ubiquitin
ligase. We propose that PP2A regulates hSecurin levels by counteracting its phosphorylation, which promotes
its degradation. Misregulation of this process may lead to the formation of tumors, in which overproduction
of hSecurin is often observed.
Securins are regulatory proteins that associate with a thiol-
protease called separase (34). Separase cleaves the Scc1/Mcd1/
Rad21 subunit of the cohesin complex and thereby brings
about the final resolution of sister chromatid cohesion during
the metaphase-to-anaphase transition of mitosis. Securins
from different eukaryotes are surprisingly divergent at the pri-
mary sequence level, and their physiological importance also
varies. Deletion of the budding yeast (PDS1) and vertebrate
(PTTG) securin genes results in increased rates of chromo-
some loss but is not necessarily lethal (26, 52, 55). On the other
hand, the securin proteins of fission yeast (Cut2) and Drosoph-
ila (PIM) are essential. In the absence of Cut2 or PIM, sister
chromatids fail to separate (16, 49). These particular securin
proteins, therefore, provide for the first time a function that is
absolutely required for sister chromatid separation, perhaps by
assisting in separase folding or localization (1, 24, 26). A uni-
versal feature of all securin proteins, however, is that they all
act as inhibitors of separase activity. In addition, release of this
inhibition occurs via their degradation at the metaphase-to-
anaphase transition (10, 12, 17, 30, 49, 51, 58). Thus, mitotic
securin degradation contributes to the temporal control of
separase activity.
Mitotic securin is targeted for degradation by a multisubunit
ubiquitin protein ligase known as the anaphase-promoting
complex or cyclosome (APC/C) (for a review, see reference
37). During mitosis, APC/C activity is controlled by the mitotic
spindle checkpoint pathway. This checkpoint ensures that se-
curin remains stable until all sister chromatids are correctly
bi-oriented on the mitotic spindle. The fact that securin stabi-
lization by activation of the mitotic spindle checkpoint pre-
vents premature sister chromatid separation has been clearly
shown in budding yeast (10, 55). In contrast, premature sister
chromatid separation in the presence of spindle poisons has
not been observed in human cells lacking securin (26), pre-
sumably because sister chromatid separation in these cells in-
volves additional securin-independent regulatory pathways. In-
deed, cyclin-dependent kinase 1 (Cdk1) can directly inhibit
separase activity in higher eukaryotes by inhibitory phosphor-
ylation (20, 48). Cdk1 inactivation, resulting from the APC/C-
dependent proteolysis of the mitotic cyclins at the metaphase-to-
anaphase transition, therefore, presumably leads to separase
activation concomitant with securin degradation.
Mammalian securin was originally described as a proto-on-
cogene because its overexpression in NIH 3T3 transfected cells
resulted in an anchorage-independent transformation in vitro
and tumor formation when transfectants were injected into
athymic nude mice (28, 36, 57). Moreover, securin is highly
expressed in many tumors (13, 23, 45, 46). However, the mech-
anism by which securin overexpression promotes tumorigenesis is
still unclear. The fact that securin regulates sister chromatid sep-
aration during cell division suggests that overproduction of se-
curin may lead to aneuploidy caused by defective sister chro-
matid separation, resulting in tumor development (26, 31).
Other mechanisms, however, may be involved. We previously
reported that securin binds p53 and that this interaction inhib-
its its apoptotic and transcriptional activities. These results
provide a mode by which securin could promote tumorigenesis.
The interaction between securin and p53 could lead directly to
the accumulation of DNA damage and subsequent develop-
ment of malignant tumors (2). Furthermore, we have recently
provided evidence that human securin, hSecurin, has a novel
role in cell cycle arrest after exposure to UV light. Irradiation
of cells causes the downregulation of hSecurin protein by, first,
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accelerating its degradation via the proteasome and, second,
reducing the efficiency of hSecurin mRNA translation. How-
ever, somewhat paradoxically, the presence of at least some
hSecurin is necessary for cell proliferation arrest following UV
treatment. Thus, an alteration of UV-induced hSecurin down-
regulation could lead directly to the accumulation of DNA
damage (43).
Securin must be strictly regulated to ensure that cell division
and the cellular response to DNA damage are correctly ac-
complished. Nevertheless, compared to the knowledge about
separase regulation, there is little information concerning the
regulation of securin. The hSecurin/hPTTG protein level has
been described as being regulated in a cell-cycle-dependent
manner, peaking in mitosis when it is phosphorylated by the
mitotic kinase Cdc2 (41). Moreover, hSecurin has been re-
ported to be an in vitro substrate of DNA-protein kinase (44).
We now show that hSecurin associates with the heterotrimeric
serine/threonine protein phosphatase 2A (PP2A) and that it is
a substrate of this phosphatase both in vitro and in vivo. Fur-
thermore, the stability of hSecurin depends on its phosphory-
lation state, such that hyperphosphorylated forms are rapidly
destroyed via the Skp1/Cul1/F-box protein complex (SCF) E3
ubiquitin ligase. We propose that PP2A prevents degradation
of hSecurin by removal of phosphate groups that target the
protein for ubiquitination and degradation by the proteasome.
MATERIALS AND METHODS
Plasmids, cloning, and sequencing. The pGAD-p27 clone was previously ob-
tained from a two-hybrid screen using hSec-E/A (residues 1 to 163) as a bait (42,
44). DNA sequencing of this clone revealed that it encoded residues 233 to 453
of the human B55 isoform of the regulatory subunit of the PP2A complex. The
p27 insert was amplified by PCR and cloned in frame with the hemagglutinin
(HA) tag of the vector pECE (15). The resulting plasmid, pECE-B55(233–453),
was sequenced to ensure the gene fusion was free of errors. pRSET-A hSec,
pRSET-A hSec-E/A, pRSET-RII, pCDNA3-hSec VSV (vesicular stomatitis
virus), pEF-hSec, and pEF-hSec KAA-DM were previously described (43, 44,
59). pSUPER, pSUPER-Cdh1, and pSUPER-Cdc20 (5) were kindly provided by
R. Agami, and pCDNA3 Flag-Cul1(1–452) (54) was provided by Z.-Q. Pan.
pCDNA3 and pEGFP-N1 were obtained from Invitrogen and BD Biosciences,
respectively.
Yeast two-hybrid screening. Saccharomyces cerevisiae strain Hf7c was cotrans-
formed with the indicated constructs by the lithium acetate method (47). Double
transformants were plated on yeast dropout medium lacking tryptophan and
leucine (47). They were grown for 3 days at 30°C. Colonies were patched on the
same medium and replica plated on Whatman 40 filters to test for -galactosi-
dase activity (4) and for growth on yeast dropout medium lacking tryptophan,
leucine, and histidine. Interaction between Snf1 and Snf4 proteins (9) was used
as a positive control.
Cell culture and lysis. HCT116, HeLa, and Cos-7 cells (from the American
Type Culture Collection) were grown in Dulbecco’s modified Eagle’s medium
(BioWhittaker) supplemented with 10% heat-inactivated fetal calf serum
(Gibco, Invitrogen) and 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml
streptomycin (BioWhittaker), in a 5% CO2 humidified atmosphere at 37°C. Cell
lysis was performed at 4°C in 150 mM NaCl, 10 mM Tris-HCl (pH 7.5), 1%
Nonidet P-40 (NP40), 10% glycerol, 1 mM sodium vanadate (Na3VO4), 20 mM
sodium pyrophosphate (PPi), 5 mM sodium fluoride, 1 mM phenylmethylsulfonyl
fluoride, 1 g/ml aprotinin, 1 g/ml pepstatin, 1 g/ml leupeptin, and 10 g/ml
chymostatin for 20 min. Extracts were centrifuged at 20,000  g for 20 min, and
supernatants were frozen in liquid nitrogen and stored at 80°C. The protein
concentration was determined using the Bradford assay (Bio-Rad).
Cell synchronization and drugs. HeLa cells enriched in the G1, S, G2, or M
phase were obtained as previously described (27). HeLa G1 cells were obtained
by incubating cells for 16 h in 6 mM butyrate (Sigma). HeLa G1/S cells were
obtained by performing a double-thymidine block (i.e., two 16-h incubations in
2.5 mM thymidine [Sigma], with an 8-h release in between). Cells enriched in S
phase were harvested 4 h after release from the second block. Cells harvested 8 h
after release were further enriched for a G2 population by rinsing extensively to
remove mitotic cells. Mitotic arrested cells were obtained by incubation for 16 h
in medium containing 5 M nocodazole. Purity of the phases was confirmed by
flow cytometry. For some experiments, cells were pretreated with the protea-
some and calpain inhibitor Ac-LLnL-CHO (LLnL; 100 M [Sigma]) and/or the
serine/threonine protein phosphatase inhibitor okadaic acid (1 M; Sigma).
Electrophoresis, Western blot analysis, and antibodies. Proteins were sepa-
rated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), and gels were electroblotted onto nitrocellulose membranes and probed
with the following antibodies: anti-hSecurin polyclonal antibody (13); anti-HA
monoclonal antibody from Roche; anti-VSV monoclonal antibody from Sigma;
anti-Cdc20 and anti-Cdc25A monoclonal and anti-Cul1 polyclonal antibodies
from Santa Cruz Biotechnology; anti-Cdh1, anti-PP2A catalytic subunit 
(PP2A-cs ), and anti-cyclin B monoclonal antibodies from BD Biosciences;
anti-PP2A-B55 / monoclonal antibody from Upstate Biotechnology; and anti-
green fluorescent protein (GFP) polyclonal antibody from Immunology Consult-
ants Laboratory. Peroxidase-coupled donkey anti-rabbit immunoglobulin G
(IgG) and sheep anti-mouse IgG were obtained from Amersham Biosciences.
Immunoreactive bands were visualized using the enhanced chemiluminescence
(ECL) Western blotting system (Amersham Biosciences) according to the man-
ufacturer’s protocol.
Affinity chromatography assays. The expression of the six-His fusion proteins
was induced in Escherichia coli BL21 (DE3) cells by incubation with 1 mM
isopropyl--D-thiogalactoside (IPTG) for 3 h at 37°C. Fusion proteins were
purified from bacterial lysates via their affinity to Ni-nitrilotriacetic acid (NTA)
agarose (QIAGEN). Cellular lysates (200 to 500 g) were incubated for 2 h with
fusion proteins (100 to 500 ng) bound to the agarose beads. Beads were washed
six times in lysis buffer, and bound proteins were eluted by the addition of
SDS-sample buffer heated at 95°C for 5 min. Finally, the samples were subjected
to SDS-PAGE.
Coimmunoprecipitation experiments. Cellular lysates (1 to 2 mg) were incu-
bated with preimmune serum for 30 min and subsequently with protein A-
Sepharose beads (Amersham Biosciences) for 1 h at 4°C. After centrifugation,
beads were discarded and supernatants were incubated for 2 h with polyclonal
anti-hSecurin or preimmune serum, followed by protein A-Sepharose beads for
1 h. Beads were washed six times with lysis buffer, and bound proteins were
solubilized by the addition of SDS-sample buffer heated at 95°C for 5 min, before
finally being subjected to SDS-PAGE.
Transient transfections and protein half-life experiments. Constructs contain-
ing hSec, hSec KAA-DM, hSec VSV, Flag-Cul1(1–452), HA B55(233–453), and
enhanced GFP (EGFP) or empty vectors were transiently transfected by elec-
troporation into Cos-7 cells, and cells were harvested 18 h posttransfection.
Lysates of transfected cells and Western blotting assessed the level of overex-
pressed proteins. Protein half-life experiments were performed by transient
transfection of Cos-7 cells. Expression of the transgenes was induced for 18 h
prior to the addition of cycloheximide (50 g/ml; Sigma) to the culture media
and subsequent harvesting of cells at the various times indicated.
Dephosphorylation assays. Cellular extracts or hSecurin immunoprecipitates,
prepared without phosphatase inhibitors (NaF, PPi, and Na3VO4), were incu-
bated for 30 min at 30°C with lambda protein phosphatase (-PP; Upstate
Biotechnology) or at 37°C with commercial PP2A (Promega), B55 immuno-
complexes, or both commercial PP2A and B55 immunocomplexes. All dephos-
phorylation assays were carried out in the presence of protease and proteasome
inhibitors to avoid nonspecific degradation. After treatment, SDS-sample buffer
was added and samples were heated at 95°C for 5 min prior to analysis by
SDS-PAGE.
Serine/threonine protein phosphatase activity assays. The activity of serine/
threonine phosphatase was determined by using a nonradioactive molybdate
dye-based phosphatase assay kit (Promega) according to the manufacturer’s
recommendations. We first obtained the corresponding immunoprecipitates, as
previously described, from lysates prepared in lysis buffer without phosphatase
inhibitors (NaF, PPi, and Na3VO4) and washed in PP2A buffer (50 mM imida-
zole, pH 7.2, 0.2 mM EGTA, 0.02% -mercaptoethanol, and 0.1 mg/ml bovine
serum albumin). Serine/threonine phosphatase activity in these immunoprecipitates
was determined by measuring in triplicate the ability of such immune complexes to
dephosphorylate a synthetic phosphothreonine peptide, RRA[pT]VA, a preferen-
tial substrate of PP2A. The assay mixtures contained PP2A buffer prepared in
phosphate-free water, 100 M phosphopeptide substrate, and okadaic acid,
when indicated, in a final volume of 300 l. The enzyme reaction was started by
adding immunoprecipitates in 35 l of phosphate-free water, and the mixture
was allowed to incubate for 2 h at 37°C. The reaction was stopped by the addition
of 300 l molybdate dye-additive mixture, and color was developed by incubating
the mixture for 30 min at room temperature. A standard curve was obtained
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using inorganic phosphate at concentrations ranging from 500 to 3,000 M.
Absorbance at 600 nm was measured, and the amount of phosphate released was
then calculated using the standard curve. Specific hSecurin immunoprecipitate
phosphatase activity was calculated by subtracting the phosphatase activity ob-
tained from the preimmune serum mock immunoprecipitation from that ob-
tained from the hSecurin.
siRNA assays. For small interfering RNA (siRNA) assays, we used pSUPER-
Cdh1 and pSUPER-Cdc20 (as well as pSUPER as a negative control) to suppress
the expression of the endogenous cdh1 and cdc20 genes (5). HeLa cells were
transiently transfected by electroporation and harvested 48 h posttransfection.
Reduction of protein levels was confirmed by Western blotting and hybridization
with the appropriate antibodies.
To inhibit pp2a-cs , we used synthetic siRNA oligonucleotides. In this case,
transient transfection of HeLa cells was carried out with 100 nM siRNA
SMARTpool PP2A-cs  or a nonspecific control pool (Upstate, Dharmacon)
using the Oligofectamine method as described by the manufacturer for adherent
cells (Invitrogen). Cells were collected 72 h after transfection and analyzed for
PP2A-cs  expression.
We also transfected HeLa cells with expression vectors for hSec VSV, HA
B55(233–453), or empty vectors, along with either siRNA SMARTpool
PP2A-cs  or a control pool siRNA using the Lipofectamine (Invitrogen)
method. Cells were collected 48 h after transfection. When indicated, LLnL was
added 24 h before harvesting of the cells.
RESULTS
hSecurin associates with protein phosphatase PP2A. A
yeast two-hybrid screen was used to identify proteins that in-
teracted with hSecurin, (residues 1 to 163) (44). Among the
positive clones isolated from a Jurkat cDNA library, we
identified one which encoded the human isoform  of the
B55 family of PP2A regulatory subunits (residues 233 to
453) (Fig. 1A). Furthermore, in vitro binding experiments
demonstrated that hSecurin also associates with the PP2A
catalytic subunit (PP2A-cs). Lysates from HeLa cells were in-
cubated with either full-length 6His-hSecurin or truncated
6His-hSecurin(1–163) bound to Ni-NTA agarose. After wash-
ing the resin, proteins were Western blotted for the detection
of PP2A-cs (Fig. 1B). PP2A from cellular extracts associated
with both full-length and truncated 6His-hSecurin proteins,
whereas there was no interaction with an irrelevant fusion
protein (6His-RII protein). Finally, we demonstrated that
endogenous hSecurin forms a complex with the PP2A catalytic
and B55 regulatory subunits by coimmunoprecipitation ex-
periments. Lysates from HeLa cells were incubated with anti-
hSecurin polyclonal antibody or with preimmune serum. The
immunoprecipitated material was detected for the presence of
the PP2A catalytic and B55 regulatory subunits (Fig. 1C).
hSecurin coimmunoprecipitated with both PP2A subunits.
Similar results were obtained with extracts from human colo-
rectal HCT116 cells (data not shown).
hSecurin associates with enzymatically active PP2A. We
tested whether PP2A associated with hSecurin is catalytically
active. To this aim, anti-hSecurin and mock preimmune serum
immunoprecipitates were obtained from lysates of HCT116
cells. Immunocomplexes were incubated with a PP2A phos-
phopeptide substrate, and the amount of released phosphate
was measured. Phosphatase activity was markedly greater in
anti-hSecurin than in mock preimmune serum immunoprecipi-
tates (Fig. 2A). This activity was highly sensitive to okadaic
acid treatment, with an inhibition of 50% obtained with 1 nM
concentration (Fig. 2B). Since the 50% inhibitory concentra-
tion (IC50) is close to the known sensitivity of PP2A, we con-
clude that the PP2A bound to hSecurin is catalytically active.
hSecurin interacts with PP2A in all phases of the cell cycle.
We wanted to determine whether PP2A associated with hSe-
curin throughout the cell cycle. To this end, HeLa cells were
arrested in G1, S, G2, and M phases and the level of PP2A that
associated with hSecurin in each phase was tested by coimmu-
noprecipitation. PP2A-cs associated with immunoprecipitated
hSecurin throughout the cell cycle, and the level of coimmu-
noprecipitated material was relative to that of hSecurin, reach-
ing a peak in metaphase-arrested cells (Fig. 3A). Likewise,
phosphatatase activity was also observed in hSecurin immuno-
precipitates at each cell cycle phase (Fig. 3B). The level of
activity was dependent on the amount of immunoprecipitated
FIG. 1. hSecurin interacts with the serine/threonine PP2A phos-
phatase. (A) hSec-E/A (residues 1 to 163 of hSecurin) interacts with
p27 (residues 233 to 453 of PP2A-B55) in a yeast two-hybrid assay.
Hf7c reporter strain was cotransformed with the indicated constructs.
The interaction between the two-hybrid proteins is indicated by growth
in the absence of histidine (dark gray patch). DBD, fusion with the
DNA-binding domain of Gal4; AD, fusion with the activation domain
of Gal4; none, empty vector. Snf1-Snf4 interaction was used as a
positive control. (B) hSecurin interacts with PP2A-cs in vitro. Six-His
fusion proteins were incubated with NP40 extracts from HeLa cells,
purified on an Ni-NTA agarose column, and their association with
PP2A-cs was determined by immunoblotting. RII is an unrelated
protein. Lys, lysate from HeLa cells. (C) hSecurin binds to the PP2A
complex in vivo. Anti-hSecurin and preimmune (PI) sera were used in
immunoprecipitations from NP40 extracts of HeLa cells. The immu-
noprecipitates (IP) were probed for the presence of PP2A-B55/,
PP2A-cs, and hSecurin. Lys, lysate from HeLa cells.
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hSecurin and was inhibited at low concentrations of okadaic
acid in all cases.
hSecurin is a substrate of PP2A both in vitro and in vivo.
Little is known about the regulation of hSecurin phosphoryla-
tion in vivo. It has been previously published that the main
phosphorylated form of hSecurin appears in cells arrested in
metaphase after treatment with nocodazole and is Cdc2 de-
pendent (41). Mitotically phosphorylated hSecurin is observed
as a band whose migration is retarded in SDS-polyacrylamide
gels. We explored the possibility that phosphorylated mitotic
hSecurin may be a substrate of PP2A. To this end, hSecurin
was immunoprecipitated from nocodazole-treated HeLa cell
extracts and incubated with commercially obtained PP2A
phosphatase. After treatment, there appeared little difference
in the relative levels of phosphorylated and nonphosphorylated
forms of hSecurin. However, lambda protein phosphatase (-
PP) was able to dephosphorylate the mitotic phosphorylated
form of hSecurin (Fig. 4A). Then, to confirm that the mitotic
phosphorylated form of hSecurin is not a substrate of PP2A,
we immunoprecipitated B55 from HeLa cell extracts and
tested its ability to dephosphorylate the mitotic phosphory-
lated form of hSecurin. Nevertheless, no effect was detected,
even when commercial PP2A was also added (Fig. 4B, upper
panel), while B55 immunoprecipitates were able to dephos-
phorylate other phosphorylated forms of hSecurin (Fig. 4B,
lower panel). Therefore, we conclude that PP2A does not
dephosphorylate the main mitotic phosphorylated form of hSe-
curin.
To further investigate whether hSecurin is a substrate of
PP2A, we treated cells with okadaic acid in order to observe
hyperphosphorylated forms of hSecurin. Cell lysates of HeLa
cells incubated in the presence of 1 M okadaic acid for 1 h 30
min prior to harvesting were immunoblotted for hSecurin de-
tection. Surprisingly, very little hSecurin could be detected
(Fig. 4C). The addition of the proteasome inhibitor Ac-LLnL-
CHO (LLnL) to cells incubated with okadaic acid, however,
revealed the presence of several retarded bands. Incubation of
cell extracts, from LLnL- and okadaic acid-treated cells, with
-PP exposed these bands as being hyperphosphorylated forms
of hSecurin. Thus, the proteasome inhibitor prevents the deg-
radation of the phosphorylated forms of hSecurin in the pres-
ence of okadaic acid. At the concentration used in this exper-
iment, okadaic acid mainly inhibits PP2A phosphatase activity,
but we cannot rule out the possibility that it could also inhibit
other phosphatases. In a more direct experiment to determine
whether PP2A has a role in the phosphorylation status of
hSecurin, we analyzed the appearance of phosphorylated
bands when the expression level of the PP2A-cs was reduced by
using siRNA. As shown in Fig. 4D, the interference of PP2A-cs
FIG. 2. hSecurin immunoprecipitates contain phosphatase activity
sensitive to okadaic acid. (A) hSecurin was immunoprecipitated from
NP40 extracts of HCT116 cells. Preimmune serum (PI) was used as a
control. Phosphatase activity level was standardized to that obtained
from immunoprecipitates (IP) using the preimmune serum. (B) Im-
munoprecipitates of hSecurin from NP40 extracts of HCT116 cells
were incubated with increasing concentrations of okadaic acid (OA).
Activities are represented as a percentage of that observed in the
control containing no OA (C). Similar findings were obtained in five
separate experiments.
FIG. 3. The phosphatase activity associated with hSecurin immu-
noprecipitates is dependent on the stage of the cell cycle and inhibited
by okadaic acid. (A) hSecurin was immunoprecipitated from extracts
of synchronized HeLa cells harvested at various cell cycle phases.
Immunoprecipitates (IP) were probed for the presence of hSecurin
and PP2A-cs. Lys, lysate from asynchronous HeLa cells. (B) Specific
phosphatase activity of hSecurin immunoprecipitates, obtained as de-
scribed for panel A, was measured in presence or absence of 1 nM
okadaic acid (OA). Phosphatase activity was calculated as the amount
of phosphate released from a synthetic phosphothreonine peptide.
When indicated, OA was added to assay mixtures. Similar findings
were obtained in five separate experiments.
4020 GIL-BERNABE´ ET AL. MOL. CELL. BIOL.
 o
n
 February 22, 2018 by USE/BCTA.G
EN UNIVERSITARIA
http://m
cb.asm
.org/
D
ow
nloaded from
 
in the presence of LLnL revealed a retarded band that was not
present in the control using scrambled sequences of siRNA.
This result strongly supports the idea that hSecurin is a sub-
strate of PP2A.
Next, we wished to determine whether the hyperphosphory-
lated forms of hSecurin observed in the presence of okadaic
acid were indeed substrates of PP2A. In order to better detect
hSecurin, we transiently transfected Cos-7 cells with epitope-
fused hSecurin VSV. Subsequently, these cells were treated
with both okadaic acid and LLnL prior to immunoprecipita-
tion of hSecurin. Like with endogenous hSecurin, hSecurin
VSV became hyperphosphorylated. However, when incu-
bated with commercial PP2A, only the faster-migrating
band was observed, showing that hSecurin is a substrate of
PP2A in vitro. Also, when incubated with itself, the relative
ratio of slowly migrating bands to the fastest migrating band
decreased, strongly suggesting that hSecurin is an in vivo
substrate of PP2A.
Phosphorylation of hSecurin triggers its degradation via the
SCF E3 ubiquitin ligase. The instability of hSecurin in cells
treated with okadaic acid, which in addition was reversed in the
presence of the proteasome inhibitor, prompted us to investi-
gate whether either the APC/C or the SCF E3 ubiquitin ligases
were required for targeting hSecurin to the proteasome for
destruction. We first tested the involvement of the APC/C in
this process, since hSecurin is a known substrate of this ubiq-
uitin ligase. hSecurin degradation by APC/C is mediated by
two degradation motifs, an RXXL destruction box (D-box)
and a KEN-box, and is only completely inhibited when both
sequences are mutated (59). Cos-7 cells, transiently transfected
FIG. 4. Specific phosphorylated forms of hSecurin, which are degraded by the proteasome in the presence of okadaic acid, are substrates of
PP2A phosphatase. (A) Phosphorylated forms of hSecurin from nocodazole-treated cells are not substrates of PP2A phosphatase. hSecurin
immunoprecipitates (IP) from nocodazole-treated HeLa cells were incubated with or without commercially obtained PP2A or lambda protein
phosphatase (-PP) prior to Western blotting for detection of hSecurin. Asyn, lysate from asynchronous HeLa cells; NZ, lysate from nocodazole-
treated HeLa cells. (B) In the upper panel, similarly to panel A, hSecurin immunoprecipitates from nocodazole-treated HeLa cells were incubated
with commercial PP2A (PP2A), B55 immunocomplexes ( IP B55), or both commercial PP2A and B55 immunocomplexes, prior to Western
blotting for detection of hSecurin. , hSecurin immunoprecipitates from nocodazole-treated HeLa cells; Asyn, lysate from asynchronous HeLa
cells; NZ, lysate from nocodazole-treated HeLa cells. (Lower panel) Cos-7 cells were transiently transfected with epitope-tagged hSecurin VSV
(hSec VSV) prior to treatment with both okadaic acid (OA), and the proteasome and calpain inhibitor Ac-LLnL-CHO (LLnL). hSecurin
immunoprecipitates from these cells were incubated either with commercial PP2A or B55 immunocomplexes. Lysates and immunoprecipitates
were Western blotted for hSecurin detection. Lane C, lysates from nontreated transfected Cos-7 cells; OALLnL, lysates from okadaic acid- and
LLnL-treated transfected Cos-7 cells. (C) HeLa cells were treated with okadaic acid, LLnL, or both for 1 h 30 min prior to treatment with or
without -PP for 30 min. Lysates were subsequently Western blotted for the detection of hSecurin. Lanes C, lysate from control untreated HeLa
cells. (D) HeLa cells were transiently transfected with pCDNA3-hSec VSV along siRNA oligonucleotides against PP2A-cs  or nonspecific control
oligonucleotides (mock) and collected after 48 h. LLnL was added 24 h after transfections. Extracts were Western blotted for PP2A-cs and
hSecurin detection. , lysate from nontransfected and nontreated HeLa cells. (E) Cos-7 cells were transiently transfected with hSec VSV prior
to treatment with both okadaic acid and LLnL. hSecurin immunoprecipitates from these cells were incubated either with (PP2A) or without
(Incub.) commercial PP2A. Lysates and immunoprecipitates were Western blotted for hSecurin detection. , nonincubated hSecurin immu-
noprecipitates. Lane C, lysates from nontreated transfected Cos-7 cells; OALLnL, lysates from okadaic acid-and LLnL-treated transfected Cos-7
cells.
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FIG. 5. Phosphorylated forms of hSecurin induced by okadaic acid are not APC/C substrates but are degraded via the SCF E3 ubiquitin ligase.
(A) Cos-7 cells transiently transfected with either hSecurin (hSec) or hSecurin with KEN-box and D-box mutations (hSec KAA-DM) were treated
with okadaic acid (OA), LLnL, or both. Extracts, where indicated, were treated with -PP for 30 min. Western-blotted extracts were detected for
hSecurin. Lanes C, lysates from nontreated transfected Cos-7 cells. (B) HeLa cells were transiently cotransfected with pSUPER-Cdh1 and
pSUPER-Cdc20 or with pSUPER alone and harvested 48 h after transfection. When indicated, okadaic acid was added 1 h 30 min before cells
were harvested. Extracts were Western blotted for the detection of Cdh1, Cdc20, hSecurin, and cyclin B. Note that the Western blot for Cdc20
shows three bands, the upper two (and most prominent) of which are cross-reactive and not specific to Cdc20. The right panel shows a Western
4022 GIL-BERNABE´ ET AL. MOL. CELL. BIOL.
 o
n
 February 22, 2018 by USE/BCTA.G
EN UNIVERSITARIA
http://m
cb.asm
.org/
D
ow
nloaded from
 
with an expression vector for the nondegradable form of hSe-
curin (hSecurin KAA-DM) as well as wild-type hSecurin, were
treated with okadaic acid, and the level of hSecurin was ana-
lyzed by Western blotting. Both hSecurin and hSecurin
KAA-DM levels were similarly reduced after okadaic acid
treatment, compared to cells that were not treated with oka-
daic acid or with both okadaic acid and LLnL (Fig. 5A). This
observation is consistent with the notion that the APC/C is not
involved in the degradation of hSecurin in cells treated with
okadaic acid.
Degradation of hSecurin via the APC/C is mediated by two
accessory proteins, Cdc20 and Cdh1. To confirm the above
result, both Cdc20 and Cdh1 transcripts were depleted by
RNA interference. HeLa cells, transiently transfected with
both pSUPER-Cdh1 and pSUPER-Cdc20 (5), were incubated
either with or without okadaic acid, and the level of hSecurin
was analyzed by Western blotting (Fig. 5B). Both Cdh1 and
Cdc20 levels were reduced, leading to an accumulation of
hSecurin and cyclin B in the absence of okadaic acid. However,
lack of both APC/C activators failed to increase the stability of
hyperphosphorylated hSecurin in okadaic acid-treated cells.
-PP treatment of extracts from transfected or interfered cells,
in order to pack all potential phosphorylated forms of hSecurin
into one band, confirmed the previous results. Thus, we con-
clude that the APC/C is not involved in targeting hSecurin for
destruction in okadaic acid-treated cells.
We subsequently entertained the possibility that hSecurin
was targeted for degradation by the proteasome via the SCF
E3 ubiquitin ligase. To this end, we used an N-terminal Cul1
fragment that blocks SCF-mediated degradation due to the
formation of catalytically inactive complexes (54). We tran-
siently transfected Cos-7 cells with a plasmid containing a Cul1
fragment encoding residues 1 to 452 [pCDNA3 Flag-Cul1(1–
452)] and confirmed that the truncated form of Cul1 led to an
accumulation of its known substrate, Cdc25A (14) (Fig. 5C,
lower panel). Next, we examined whether it was able to block
securin degradation after okadaic acid treatment. The expres-
sion of Flag-Cul1(1–452) led reproducibly to an increase of
securin after okadaic acid treatment that was especially visible
after the retarded phosphorylated forms of securin were re-
duced to a single band after -PP treatment. Similar results
were obtained by using ectopically expressed hSecurin (Fig.
5C). These results are consistent with the notion that securin is
a substrate of the SCF complex that targets phosphorylated
forms of securin for destruction. In fact, endogenous hSecurin
and Cul1 proteins coimmunoprecipitated from HeLa cells
(Fig. 5D).
PP2A stabilizes hSecurin via the B55 regulatory subunit.
Two observations point to an involvement of PP2A in stabiliz-
ing cellular levels of hSecurin. First, PP2A containing the B55
regulatory subunit directly binds to hSecurin. Second, okadaic
acid, a potent inhibitor of PP2A phosphatase, both prevents
dephosphorylation of hSecurin and promotes its proteasomal
degradation (see above). To address this possibility, we first
analyzed the level of securin in cells overexpressing B55 reg-
ulatory protein. If B55 directly targets PP2A-cs to hSecurin,
its overexpression should direct a larger portion of the cellular
pool of catalytic PP2A subunits to dephosphorylate and thus
stabilize hSecurin. We directly compared the amount of se-
curin in mock transiently transfected cells (pECE) with that in
cells transiently transfected with a construct containing a trun-
cated form of B55 comprising residues 233 to 453 [pECE-
B55(233–453)]. This region included the conserved binding
domain 2 that is able to bind the scaffold A subunit of PP2A,
which in turn binds to PP2A-cs (32). Overexpression of
B55(233–453) caused a dramatic and specific increase in the
level of endogenous securin, while cyclin B levels were not
altered (Fig. 6A, left panels). To discount the possibility that
this accumulation was due to increased transcriptional or
translational activity of the endogenous hSecurin gene, we
analyzed the effect of the overexpression of B55 on ectopi-
cally expressed hSecurin, using a constitutive heterologous
promoter. Ectopic hSecurin also accumulated to high levels in
such cells (Fig. 6A, right panels).
Next, we measured the hSecurin half-life in cells overex-
pressing B55(233–453). To this end, Cos-7 cells were tran-
siently cotransfected with pCDNA3-hSec VSV and either
pECE or pECE-B55(233–453) plasmid. Expression was in-
duced for 18 h, cycloheximide was added to the media, and
cells were collected over a 2-h period. As expected, the half-life
of hSecurin VSV was higher in cells expressing B55 than in
mock-treated cells (Fig. 6B). Thus, increased levels of the B55
form of PP2A are sufficient to lead to an accumulation of
hSecurin due to promoting its stability.
Although we previously showed that okadaic acid treatment
of HeLa cells resulted in reduced levels of hSecurin, it is
possible that not only was PP2A phosphatase activity inhibited,
but so was that of other phosphatases that are also sensitive to
this drug. To test the specific role of PP2A in hSecurin stability,
we analyzed the level of hSecurin when PP2A expression was
specifically inhibited by using RNA interference. siRNA di-
rected against the catalytic subunit of PP2A efficiently reduced
the level of endogenous PP2A-cs. Coincident with this reduc-
tion, the amount of hSecurin was dramatically decreased (Fig.
6C). In contrast, scrambled sequences of siRNA (mock) had
no effect on the level of the PP2A-cs and did not alter the
hSecurin level. Moreover, cyclin B levels were again unaltered.
In contrast, scrambled sequences of siRNA (mock) had no
effect on the level of the PP2A-cs and did not alter the hSe-
curin level. Moreover, cyclin B levels were again unaltered.
blot of extracts which were treated with -PP. , lysates from nontransfected HeLa cells. (C) In the left panels, Cos-7 cells transiently transfected
with pCDNA3 or pCDNA3 Flag-Cul1(1–452) were treated either with (lanes OA) or without (lanes C) okadaic acid before harvesting. NP40
extracts were prepared and were Western blotted for Cul1, Flag-Cul1(1–452), and securin detection. Where indicated, extracts were treated with
-PP. Expression of Cdc25A was also tested in Cos-7-transfected cells. (Right panels) Cos-7 cells transiently transfected with the indicated plasmids
were treated either with (lanes OA) or without (lanes C) okadaic acid before harvesting. NP40 extracts were prepared and were Western blotted
for Cul1, Flag-Cul1(1–452), hSec VSV, and EGFP detection. Where indicated, extracts were treated with -PP. (D) Anti-hSecurin and preimmune
(PI) sera were used in immunoprecipitations from NP40 extracts of LLnL-treated Cos-7 cells. The immunoprecipitates (IP) were probed for the
presence of Cul1 and hSecurin. Lys, lysate from LLnL-treated Cos-7 cells; IgG, the IgG heavy chains.
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Finally, we investigated whether the hSecurin stabilization ob-
served after overexpression of B55 was simply due to its
binding to hSecurin or to its protection against phosphoryla-
tion. To this aim, we analyzed the effect of the B55 regulatory
subunit on hSecurin stability under conditions that do not
allow PP2A-cs to act over hSecurin. B55 was overexpressed,
and simultaneously PP2A-cs was interfered with by siRNA. As
shown in Fig. 6D, the overexpression of B55 not only did not
increase the hSecurin level, but even this level was lower than
the basal one. Taken together, these results demonstrate that
PP2A contributes to stabilization of hSecurin by dephosphory-
lating phospho-residues that promote its degradation through
the SCF ubiquitin pathway.
DISCUSSION
The experiments described in this paper show that human
securin can associate with the fully assembled, enzymatically
active PP2A holoenzyme. We identified through a yeast two-
hybrid screen, using hSecurin as bait, the B55 regulatory
subunit of PP2A. Pull-down and coimmunoprecipitation assays
demonstrated that hSecurin interacts specifically with the
PP2A complex both in vitro and in vivo and that this associa-
tion does not depend on the cell cycle phase. Among the
proteins shown to associate with PP2A and regulate its activity
are the small t antigens encoded by SV40 and polyomavirus,
the adenovirus E4orf4 protein, casein kinase II, and Hox II
(19). In some cases, the interaction results in a negative regu-
lation of PP2A activity. Although we have not determined its
effect on the specific activity of PP2A, hSecurin clearly does
not block its enzymatic activity.
Our discovery that hSecurin associates with enzymatically
active PP2A provided the impetus for testing whether phos-
phorylated hSecurin might serve as a substrate of PP2A.
Our data strongly support the conclusion that this is the
case. Experiments performed in vitro using a commercial
source of PP2A and phosphorylated hSecurin as a substrate
revealed that PP2A is able to dephosphorylate the various
forms of phosphorylated hSecurin obtained from okadaic
acid-treated cells but not the main phosphorylated form of
hSecurin obtained from mitotically arrested nocodazole-
treated cells. Thus, the ability of PP2A to dephosphorylate
FIG. 6. The PP2A phosphatase complex stabilizes hSecurin. (A) Cos-7 cells were transiently transfected with either empty vector (pECE) or
pECE-B55(233–453). Endogenous securin levels (upper left panel) or cotransfected hSecurin VSV (pCDNA3-hSec VSV; upper right panel) was
detected in immunoblotted lysates. EGFP (pEGFP-N1; right panel) was used as an internal control for transfection efficiency. (B) Cos-7 cells were
transiently cotransfected with hSecurin VSV (hSec VSV) and either HA B55 [pECE-B55(233–453)] or empty vector (pECE), and their
expression was induced for 18 h. Cycloheximide (CHX; 50 g/ml) was added to the media to inhibit protein synthesis, and cells were collected at
the indicated times after addition of CHX. hSecurin VSV levels in cell lysates were detected by immunoblotting with anti-VSV monoclonal
antibody. (C) HeLa cells were transiently transfected with siRNA oligonucleotides against PP2A-cs  or nonspecific control oligonucleotides
(mock) and collected after 72 h. Western blots of extracts were analyzed for PP2A-cs, hSecurin, and cyclin B levels. , extract from noninterfered
HeLa cells. (D) HeLa cells were transiently transfected with the indicated plasmids along siRNA oligonucleotides against PP2A-cs  or nonspecific
control oligonucleotides (mock) and collected after 48 h. Extracts were Western blotted for PP2A-cs and hSecurin detection.
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hSecurin is probably dependent on the specific phosphory-
lated residue.
The observation that okadaic acid treatment of cells results
in the destabilization of hSecurin suggests that PP2A may
regulate hSecurin stability. Okadaic acid has been shown to
preferentially inhibit PP2A at the low concentration used in
these experiments. However, we cannot rule out that okadaic
acid does not inhibit to some degree the other major serine-
threonine phosphatases PP1, PP2B/calcineurin, and PP2C or
other less-well-characterized phosphatases (11). Nevertheless,
two observations strongly implicate PP2A in the regulation of
hSecurin stability. First, decreasing cellular PP2A activity, as a
result of using RNA interference against the catalytic subunit
of PP2A, leads to a reduction in hSecurin levels. Second, in-
creasing the cellular levels of the PP2A regulatory subunit
B55 promotes the accumulation of hSecurin by reducing its
turnover, and which is very meaningful, this B55 effect re-
quires the phosphatase activity of PP2A. Moreover, the effect
of PP2A on the stabilization of hSecurin is not a consequence
of the influence of PP2A on the cell cycle progression, since
cyclin B levels remain unchanged in either cells overexpressing
B55 or cells with reduced levels of PP2A-cs. In conclusion, we
propose that the association of PP2A to hSecurin leads to
hSecurin stabilization via its dephosphorylation.
It has been well documented that PP2A activity is important
for the regulation of the stability of the proto-oncogenic tran-
scription factor c-Myc. The fine tuning of c-Myc expression
occurs at the protein level through modulation of its stability
(3, 21). The half life of c-Myc polypeptides is determined
largely by phosphorylation of two specific residues found in all
mammalian Myc family members, which results in its degra-
dation via the ubiquitin proteasome pathway (21, 40). PP2A
was shown to be required to dephosphorylate c-Myc at serine
62, leading to its proteolysis (56). Another example of proteins
in which PP2A regulates their stability is the Pim family of
protein kinases. The Pim kinases associate with the catalytic
subunit of PP2A in vivo and are substrates of PP2A phos-
phatase in vitro. Overexpression of PP2A decreases the steady-
state levels of the Pim proteins, and the inhibition of PP2A
activity by okadaic acid enhances the stability of Pim-1 (33).
In an attempt to determine the effect of okadaic acid
treatment, and thus PP2A action, on the phosphorylation
status of hSecurin, we found that not only was hSecurin
hyperphosphorylated, but the various hyperphosphorylated
forms were extremely unstable, being rapidly degraded by the
proteasome. Knowing that the APC/C E3 ubiquitin ligase tar-
gets hSecurin for destruction during anaphase and mitotic exit,
we naturally studied its involvement in okadaic acid-mediated
instability of hSecurin. To be fully active, APC/C requires two
additional subunits that regulate its target specificity, Cdc20
and Cdh1, thus forming two distinct complexes (APC/CCdc20
and APC/CCdh1) (37). Target specificity is due to the ability of
Cdc20 and Cdh1 to recognize two specific destruction se-
quences on APC/C substrates, namely the D-box and KEN-box
motifs (18, 39). hSecurin degradation is catalyzed by both
Cdc20 and Cdh1, is mediated by a D-box and a KEN-box, and
is inhibited only when both sequences are mutated (59). Our
results demonstrate that degradation of phospho-hSecurin,
produced during okadaic acid treatment, is not dependent on
the APC/C. First, the nondegradable form of hSecurin (with
both D- and KEN-box motifs mutated) is not resistant to
okadaic acid-mediated degradation. Second, the depletion of
both APC/C activators, Cdc20 and Cdh1, by siRNA was not
able to block the degradation of phospho-hSecurin. We thus
turned to investigate the involvement of other ubiquitin ligases
in this degradation process. Knowing that the action of the
SCF ubiquitin ligase complex is tightly coupled to substrate
phosphorylation status, we decided to study whether the SCF
plays a role in the degradation of phospho-hSecurin. The SCF
ligase has a broad function in many physiological processes by
ubiquitinating proteins involved in, for example, cell cycle reg-
ulation, transcription, and signal transduction (22, 29, 38). Re-
cruitment of substrates to the SCF complex occurs via one of
a variety of F-box protein subunits, which function as molec-
ular adaptors (8, 53). F-box proteins interact via the F-box
motif with the Skp1 subunit, which can bridge the F-box to the
cullin (35), which in turn serves as a scaffold to bring the
catalytic RING finger protein to the substrate (50). Substrate
recognition by the F-box protein is mediated in most cases by
phosphorylation of target proteins (22, 25).
To test the possible involvement of the SCF in mediating
hSecurin degradation in okadaic acid-treated cells, we made
use of a dominant-negative N-terminal Cul1 mutant that in-
terferes with the degradation of SCF substrates (54). Upon
expression of this mutant by transient transfection, hSecurin
was substantially stabilized in okadaic acid-treated cells. This
result provides evidence that the SCF is involved in the pro-
teolysis of phospho-hSecurin and indicates that the abundance
of hSecurin in the cell is regulated not only by the APC/C
during metaphase and mitotic exit, but also by the SCF at other
cell cycle stages. Such a dual mode of degradation has been
described for the Cdc25A phosphatase, an activator of cell
cycle progression. Both the APC/C and the SCF are involved in
Cdc25A turnover. While the APC/C degrades Cdc25A during
mitotic exit, SCF regulates its abundance in the S and G2
phases. Moreover, in response to DNA damage or to stalled
replication, the activation of the ATM and ATR protein ki-
nases results in Chk1 and Chk2 activation and Cdc25A hyper-
phosphorylation that stimulate SCF-mediated ubiquitination
of Cdc25A and its proteolysis (6, 7, 14). In this context, it is
worth mentioning that hSecurin is also degraded in response to
irradiation (43). The new findings reported here raise addi-
tional important questions that will need to be addressed in the
future. These include the nature of the phosphorylation events
that trigger hSecurin degradation and the role of SCF ubiq-
uitination in regulating hSecurin levels during a normal cell
cycle as well as in response to DNA damage. Unraveling the
mechanisms involved in regulating hSecurin stability is of ad-
ditional interest in that it may contribute to explaining the
cause of the high hSecurin levels detected in many tumors,
since no mutations in its promoter or in its open reading frame
have been found to date, and it may further our understanding
of how such high levels lead to oncogenesis.
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